Online citations, reference lists, and bibliographies.
← Back to Search

A Review Of Coumarin Derivatives In Pharmacotherapy Of Breast Cancer.

M. Musa, J. Cooperwood, M. O. Khan
Published 2008 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
The coumarin (benzopyran-2-one, or chromen-2-one) ring system, present in natural products (such as the anticoagulant warfarin) that display interesting pharmacological properties, has intrigued chemists and medicinal chemists for decades to explore the natural coumarins or synthetic analogs for their applicability as drugs. Many molecules based on the coumarin ring system have been synthesized utilizing innovative synthetic techniques. The diversity oriented synthetic routes have led to interesting derivatives including the furanocoumarins, pyranocoumarins, and coumarin sulfamates (COUMATES), which have been found to be useful in photochemotherapy, antitumor and anti-HIV therapy, and as stimulants for central nervous system, antibacterials, anti-inflammatory, anti-coagulants, and dyes. Of particular interest in breast cancer chemotherapy, some coumarins and their active metabolite 7-hydroxycoumarin analogs have shown sulfatase and aromatase inhibitory activities. Coumarin based selective estrogen receptor modulators (SERMs) and coumarin-estrogen conjugates have also been described as potential antibreast cancer agents. Since breast cancer is the second leading cause of death in American women behind lung cancer, there is a strong impetus to identify potential new drug treatments for breast cancer. Therefore, the objective of this review is to focus on important coumarin analogs with antibreast cancer activities, highlight their mechanisms of action and structure-activity relationships on selected receptors in breast tissues, and the different methods that have been applied in the construction of these pharmacologically important coumarin analogs.
This paper references
10.1126/SCIENCE.126.3280.969-A
Coumestrol, a new estrogen isolated from forage crops.
E. Bickoff (1957)
10.1016/s0021-9258(18)50153-8
Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase.
R. Kitz (1962)
10.1021/JM00334A010
CENTRAL NERVOUS SYSTEM DEPRESSANTS. VII. PYRIDYL COUMARINS.
R. Moffett (1964)
10.1016/S0039-128X(68)80103-5
The oestrogenic and anti-oestrogenic activity of some synthetic steroids and non-steroids.
I. Pollard (1968)
10.1021/JO00967A017
Mirestrol. I. Preparation of the tricyclic intermediate.
M. Miyano (1972)
Inhibition and enhancement of mammary tumorigenesis by 7,12-dimethylbenz (a) anthracene in the female sprague-dawley rat.
G. Feuer (1974)
10.1016/S0031-9422(00)84429-5
Progress in the chemistry of organic natural products
J. Harborne (1975)
10.1159/000225098
Suppression of 7,12-Dimethylbenz(α) Anthracene-Induced Breast Carcinoma by Coumarin in the Rat
G. Feuer (1976)
10.1038/267056A0
Melanotropin–daunomycin conjugate shows receptor-mediated cytotoxicity in cultured murine melanoma cells
J. Varga (1977)
Inhibition of Chemical Carcinogen-induced Neoplasia by Coumarins and α-Angelicalactone
L. Wattenberg (1979)
10.1056/NEJM198001033020104
Cancer of the breast: the past decade (first of two parts).
I. Henderson (1980)
The natural coumarins : occurrence, chemistry, and biochemistry
R. D. Murray (1982)
10.1210/JCEM-59-1-29
In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway.
S. Santner (1984)
10.1016/0022-4731(89)90077-0
Importance of estrogen sulfates in breast cancer.
J. Pasqualini (1989)
Realizing the full potential of immunotoxins.
W. Blättler (1989)
10.1021/JM00127A022
Diethylstilbestrol-linked cytotoxic agents: synthesis and binding affinity for estrogen receptors.
K. Krohn (1989)
10.1177/096032718900800612
The Rarity of Liver Toxicity in Patients Treated with Coumarin (1, 2-Benzopyrone)
D. Cox (1989)
10.3109/03602539008991449
The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds.
D. Egan (1990)
10.1016/0960-0760(90)90460-3
Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor
A. Bhatnagar (1990)
10.1016/0006-2952(90)90723-X
Metabolism of the 4-iodo derivative of tamoxifen by isolated rat hepatocytes. Demonstration that the iodine atom reduces metabolic conversion and identification of four metabolites.
R. Mccague (1990)
Phase I evaluation of coumarin (1,2-benzopyrone) and cimetidine in patients with advanced malignancies.
M. Marshall (1991)
10.1016/0006-2952(92)90002-Z
Interactions of a series of coumarins with reactive oxygen species. Scavenging of superoxide, hypochlorous acid and hydroxyl radicals.
M. Payá (1992)
10.1016/0163-7258(92)90051-Z
Multistage carcinogenesis in mouse skin.
J. DiGiovanni (1992)
10.1002/PROS.2990200208
Phase II evaluation of coumarin (1,2‐benzopyrone) in metastatic prostatic carcinoma
J. Mohler (1992)
10.1056/NEJM199310143291604
Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone.
J. Casley-Smith (1993)
10.1021/JM00048A016
Peptide-linked 1,3-dialkyl-3-acyltriazenes: gastrin receptor directed antineoplastic alkylating agents.
B. Schmidt (1994)
10.1002/1097-0142(19940801)74:3<864::AID-CNCR2820740312>3.0.CO;2-N
Estrogen receptors (ER) in human breast cancer. The significance of a new prognostic factor based on both ER protein and ER mRNA contents
M. Gotteland (1994)
10.1021/BI00036A025
Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-O-sulfamate.
A. Purohit (1995)
10.5694/j.1326-5377.1995.tb139958.x
Frequency of coumarin hepatotoxicity
John R. Casley‐Smith (1995)
10.1016/0092-8674(95)90314-3
A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency
B. Schmidt (1995)
Comprehensive heterocyclic chemistry II
A. Katritzky (1996)
Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities.
R. Tekmal (1996)
10.1016/0959-8049(95)00013-5
New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity.
M. Castiglione-Gertsch (1996)
10.1016/0306-3623(95)02112-4
Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential.
J. Hoult (1996)
10.1038/bjc.1996.129
Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases.
I. Soubeyran (1996)
10.1016/0959-8049(95)00014-3
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
W. Jonat (1996)
In vivo activity of 4-methylcoumarin-7-O-sulfamate, a nonsteroidal, nonestrogenic steroid sulfatase inhibitor.
A. Purohit (1996)
10.1002/CHIN.199649243
Design, Synthesis, and Biological Evaluation of Ellipticine‐Estradiol Conjugates.
R. Devraj (1996)
10.1021/JM950931Z
Active site directed inhibition of estrone sulfatase by nonsteroidal coumarin sulfamates.
L. Woo (1996)
10.1038/bjc.1996.531
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
J. Geisler (1996)
10.1016/S0960-0760(96)00093-3
Synthesis and sulfatase inhibitory activities of non-steroidal estrone sulfatase inhibitors
P. Li (1996)
10.1210/endo.138.3.4979
Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors α and β.
G. Kuiper (1997)
10.1210/JC.82.1.200
Aromatase activity and expression in breast cancer and benign breast tissue stromal cells.
S. J. Santner (1997)
10.1016/S0969-2126(97)00185-8
Structure of a human lysosomal sulfatase.
C. S. Bond (1997)
10.1515/znc-1997-3-416
Structure -Cytotoxicity Relationships of a Series of Natural and Semi-Synthetic Simple Coumarins as Assessed in Two Human Tumour Cell Lines
H. Kolodziej (1997)
10.1093/CARCIN/18.8.1521
Effect of naturally occurring coumarins on the formation of epidermal DNA adducts and skin tumors induced by benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene in SENCAR mice.
Y. Cai (1997)
Comprehensive heterocyclic chemistry on CD-ROM
A. Katritzky (1997)
10.1016/S0960-0760(97)00196-9
The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity
A. Purohit (1998)
10.1074/jbc.273.11.6096
Sulfatases, Trapping of the Sulfated Enzyme Intermediate by Substituting the Active Site Formylglycine *
M. Recksiek (1998)
Antitumor-activities of coumarin, 7-hydroxy-coumarin and its glucuronide in several human tumor cell lines.
U. Weber (1998)
10.1021/BI9714924
Crystal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis.
G. Lukatela (1998)
10.1002/CHIN.199826318
Selective estrogen receptor modulators (SERMs).
T. Grese (1998)
10.1016/S0960-894X(98)00477-6
Novel antineoplastic agents with efficacy against multidrug resistant tumor cells.
J. Medina (1998)
10.1021/BI9810205
Residues critical for formylglycine formation and/or catalytic activity of arylsulfatase A.
A. Knaust (1998)
In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.
J. Geisler (1998)
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
A. Brodie (1998)
10.1021/JM970527V
Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase.
L. Woo (1998)
10.1042/BST0260054
Definition of the molecular mechanism of action of tissue-selective oestrogen-receptor modulators.
D. McDonnell (1998)
10.1016/S0968-0896(97)10053-0
Comparative molecular field analysis of non-steroidal aromatase inhibitors: an extended model for two different structural classes.
M. Recanatini (1998)
10.1073/PNAS.96.10.5686
Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors.
B. Shan (1999)
10.1007/BF03343619
Postmenopausal hormone therapy, SERMs, and coronary heart disease in women
Nanette K. Wenger (1999)
10.1210/endo.140.12.7164
Comparative Analyses of Mechanistic Differences Among Antiestrogens1.
A. Wijayaratne (1999)
[Binding affinity to steroid hormone receptors and antiproliferative action on MCF-7 cells of coumarin derivatives and isoflavonoids].
S. Kirkiacharian (1999)
Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer.
T. Utsumi (1999)
10.1016/S1043-2760(99)00177-0
The Molecular Pharmacology of SERMs
D. McDonnell (1999)
10.1677/ERC.0.0060205
Aromatase inhibitors and their antitumor effects in model systems.
A. Brodie (1999)
10.1677/ERC.0.0060307
Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands.
R. Tekmal (1999)
10.1016/S0027-5107(99)00012-3
Estrogen, DNA damage and mutations.
D. Roy (1999)
10.1016/S0960-894X(99)00390-X
Synthesis and estrogen receptor binding affinity of a porphyrin-estradiol conjugate for targeted photodynamic therapy of cancer.
D. James (1999)
10.1677/ERC.0.0060235
The potential of aromatase inhibitors in breast cancer prevention.
R. Santen (1999)
10.1016/S0165-0173(99)00021-1
Actions of dehydroepiandrosterone and its sulfate in the central nervous system: effects on cognition and emotion in animals and humans
O. Wolf (1999)
Trends Endocrinol. Metab
DP McDonnell (1999)
10.1634/THEONCOLOGIST.5-5-388
Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects.
D. Muchmore (2000)
In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE.
A. Purohit (2000)
10.1016/S0960-894X(00)00304-8
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
B. Musicki (2000)
10.1016/S0960-0760(00)00178-3
Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates
B. Malini (2000)
10.1016/S0960-894X(00)00144-X
New fluorogenic substrate for the first continuous steroid sulfatase assay.
M. Bilban (2000)
10.1016/S1074-5521(00)00023-5
Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates.
L. Woo (2000)
10.1200/JCO.2000.18.17.3172
Selective estrogen receptor modulators: structure, function, and clinical use.
C. Osborne (2000)
10.1016/S0303-7207(00)00428-7
Non-steroidal and steroidal sulfamates: new drugs for cancer therapy
A. Purohit (2001)
10.1016/S0960-0760(01)00066-8
In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer
T. L. Taras (2001)
10.1093/HUMUPD/7.3.273
Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development.
J. Liehr (2001)
10.1046/J.1432-1033.2001.01886.X
Evaluation of the mechanism of aromatase cytochrome P450. A site-directed mutagenesis study.
Y. C. Kao (2001)
10.1002/CHIN.200135168
Substituted Benzopyranobenzothiazinones. Synthesis and Estrogenic Activity on MCF‐7 Breast Carcinoma Cells.
Y. Jacquot (2001)
10.1023/A:1013128213451
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.
W. Eiermann (2001)
10.1021/JM001119L
Flexible estrogen receptor modulators: design, synthesis, and antagonistic effects in human MCF-7 breast cancer cells.
M. J. Meegan (2001)
10.1006/JMBI.2000.4297
Crystal structure of an enzyme-substrate complex provides insight into the interaction between human arylsulfatase A and its substrates during catalysis.
R. von Bülow (2001)
Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models.
H. Brady (2002)
10.2174/0929867023371210
Review of estrone sulfatase and its inhibitors--an important new target against hormone dependent breast cancer.
Sabbir Ahmed (2002)
10.1210/ER.2001-0040
Sulfonation and molecular action.
C. Strott (2002)
10.1007/978-3-7091-6172-2_1
The naturally occurring coumarins.
R. D. Murray (2002)
10.1016/S0960-0760(02)00037-7
Synthesis and biochemical evaluation of novel and potent inhibitors of the enzyme oestrone sulphatase (ES)
Sabbir Ahmed (2002)
10.1016/S0959-8049(02)00278-2
SERMs: how do they work?
M. Draper (2002)
10.1016/S0960-894X(02)00798-9
Natural and synthetic geiparvarins are strong and selective MAO-B inhibitors. Synthesis and SAR studies.
A. Carotti (2002)
10.1124/MOL.61.3.562
Differential Response of Estrogen Receptors α and β to SP500263, a Novel Potent Selective Estrogen Receptor Modulator
H. Brady (2002)
10.1016/S0968-0896(02)00242-0
An estradiol-porphyrin conjugate selectively localizes into estrogen receptor-positive breast cancer cells.
N. Swamy (2002)
38(Suppl 6):S35
MW Draper (2002)
10.1016/S1043-4666(03)00179-0
SP500263, a novel SERM, blocks osteoclastogenesis in a human bone cell model: role of IL-6 and GM-CSF.
M. K. Kung Sutherland (2003)
10.1186/bcr746
Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer
N. Yoshimura (2003)
10.1016/S0960-0760(03)00046-3
In vitro and in vivo models for the evaluation of new inhibitors of human steroid sulfatase, devoid of residual estrogenic activity
J. Shields-Botella (2003)
High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer.
Y. Miyoshi (2003)
10.1016/S0960-0760(03)00372-8
Aromatase inhibitors as adjuvant therapies in patients with breast cancer
R. Coombes (2003)
10.2174/0929867033457647
Anticancer and antiviral sulfonamides.
A. Scozzafava (2003)
10.1016/S0960-0760(03)00049-9
Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate
B. Raobaikady (2003)
[Synthesis and binding affinity of 3-aryl-7-hydroxycoumarins to human alpha and beta estrogen receptors].
S. Kirkiacharian (2003)
Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma.
T. Suzuki (2003)
10.1186/1475-2867-3-10
17β-Estradiol responsiveness of MCF-7 laboratory strains is dependent on an autocrine signal activating the IGF type I receptor
I. H. Hamelers (2003)
10.1016/S0960-0760(03)00353-4
Steroid sulphatase inhibitors for breast cancer therapy
A. Purohit (2003)
10.1016/S0960-894X(03)00009-X
Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II.
N. Vicker (2003)
10.1016/S0223-5234(03)00086-2
Cytotoxic effects, alkylating properties and molecular modelling of coumarin derivatives and their phosphonic analogues.
E. Budzisz (2003)
10.1016/S0960-894X(03)00490-6
Novel coumarin derivatives of heterocyclic compounds as lipid-lowering agents.
G. R. Madhavan (2003)
10.1016/J.BEEM.2003.08.002
The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
S. Howell (2004)
10.1016/j.tem.2004.05.007
Genotoxicity of steroidal estrogens
J. Russo (2004)
10.1016/S1535-6108(04)00059-5
Selective estrogen receptor modulation: concept and consequences in cancer.
V. Jordan (2004)
10.1002/MED.20008
Steroid sulfatase inhibitors
P. Nussbaumer (2004)
10.1016/J.FARMAC.2004.08.004
Synthesis and binding affinity to human α and β estrogen receptors of various 7-hydroxycoumarins substituted at 4- and 3,4- positions
S. Kirkiacharian (2004)
10.1021/NP030296X
Design, synthesis, and bioactivities of steroid-linked taxol analogues as potential targeted drugs for prostate and breast cancer.
Changhui Liu (2004)
10.1007/BF00682744
Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients
L. Demers (2004)
10.1007/BF00682745
Arimidex®: A potent and selective fourth-generation aromatase inhibitor
P. Plourde (2004)
10.1016/J.BMCL.2004.04.081
Lead identification of a potent benzopyranone selective estrogen receptor modulator.
J. A. Mckie (2004)
10.1002/CHIN.200409113
Synthesis and Relative Binding Affinity to Human Steroid Receptors of Substituted 3‐Aryloxycoumarins.
R. Bakhchinian (2004)
10.1021/JM049535J
Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors.
F. Leonetti (2004)
10.2174/1381612043382693
Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer.
A. Lacy (2004)
10.2174/1381612043382710
Natural and synthetic coumarin derivatives with anti-inflammatory/ antioxidant activities.
K. Fylaktakidou (2004)
10.1074/JBC.M406847200
Biochemical and Biological Characterization of a Novel Anti-aromatase Coumarin Derivative*
S. Chen (2004)
10.1016/J.BREAST.2004.09.003
Are all aromatase inhibitors the same? A review of the current evidence.
F. Jänicke (2004)
10.1016/J.BMCL.2004.05.016
Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity.
N. Reddy (2004)
10.1016/J.BMC.2005.02.051
Novel coumarin-3-(N-aryl)carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1.
N. Reddy (2005)
10.1021/JP044851V
Photophysical and (photo)electrochemical properties of a coumarin dye.
Z. Wang (2005)
10.2174/1568011053352622
Chemical aspects of coumarin compounds for the prevention of hepatocellular carcinomas.
T. Okamoto (2005)
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
H. Mouridsen (2005)
10.1042/BJ20041037
Crystal structure of human carbonic anhydrase II at 1.95 A resolution in complex with 667-coumate, a novel anti-cancer agent.
M. Lloyd (2005)
10.2174/0929867053507315
Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity.
F. Borges (2005)
10.1007/BF01377124
An updated review of the clinical development of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin
M. Marshall (2005)
10.1007/BF01377122
Treatment with coumarin to prevent or delay recurrence of malignant melanoma
R. Thornes (2005)
10.1210/ER.2004-0003
Steroid sulfatase: molecular biology, regulation, and inhibition.
M. Reed (2005)
10.1507/ENDOCRJ.53.7
Pharmaceutical prospects of phytoestrogens.
T. Usui (2006)
10.1155/BCA/2006/68274
Structure-Activity Relationships of Synthetic Coumarins as HIV-1 Inhibitors
I. Kostova (2006)
10.1158/1078-0432.CCR-05-1996
Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor
S. Stanway (2006)
10.1016/j.jsbmb.2006.09.012
What do we know about the mechanisms of aromatase inhibitor resistance?
Shiuan Chen (2006)
10.1016/J.BMCL.2005.10.004
Synthesis and biological activities of nucleoside-estradiol conjugates.
H. Ali (2006)
10.1200/JCO.2006.24.18_SUPPL.1014
Aromatase inhibition and very low dose estradiol add-back: A pilot study for novel breast cancer prevention.
A. Kendall (2006)
10.1155/BCA/2006/25651
Synthesis, Characterization, and Cytotoxic Activity of New Lanthanum(III) Complexes of Bis-Coumarins
I. Kostova (2006)
10.1016/j.jsbmb.2007.05.023
Summary of aromatase inhibitor trials: The past and future
P. Goss (2007)
10.1016/J.BMCL.2007.03.016
Synthesis, characterization, and estrogen receptor binding affinity of flavone-, indole-, and furan-estradiol conjugates.
Naseem Ahmed (2007)
10.1016/J.BMCL.2007.06.083
Antitumor agents. 258. Syntheses and evaluation of dietary antioxidant--taxoid conjugates as novel cytotoxic agents.
Kyoko Nakagawa-Goto (2007)
10.1016/J.EJMECH.2007.05.005
Synthesis, computational study and cytotoxic activity of new 4-hydroxycoumarin derivatives.
S. Stanchev (2008)



This paper is referenced by
10.1134/S1070428021060154
Synthesis, Characterization, and Cytotoxic Evaluation of New Triazole Derivatives of Osthol
Z. Rather (2021)
10.1016/J.MOLSTRUC.2021.130424
Design and synthesis of new series of dipyrromethane-coumarin and porphyrin-coumarin derivatives: Excellent anticancer agents
Megharaja Holiyachi (2021)
10.1016/J.MOLSTRUC.2020.129289
Synthesis and evaluation of the antagonistic activity of 3-acetyl-2H-benzo[g]chromen-2-one against mutant Y537S estrogen receptor alpha via E-Pharmacophore modeling, molecular docking, molecular dynamics, and in-vitro cytotoxicity studies
R. Shylaja (2021)
10.3390/molecules26041121
Phytochemical Investigation of New Algerian Lichen Species: Physcia Mediterranea Nimis
M. Kerboua (2021)
10.1039/D0NJ04670A
In vitro and in silico molecular docking studies of Rheum emodi-derived diamagnetic SnO2 nanoparticles and their cytotoxic effects against breast cancer
D. Sharma (2021)
10.1080/00397911.2021.1925917
An efficient approach for the synthesis and antimicrobial evaluation of some new benzocoumarins and related compounds
Mohamed H. Hekal (2021)
10.1016/J.JPHOTOCHEM.2020.112956
Quantum chemical computations, fluorescence spectral features and molecular docking of two biologically active heterocyclic class of compounds
R. Melavanki (2021)
10.1016/j.heliyon.2021.e06656
Deverra tortuosa (Desf.) DC from Saudi Arabia as a new source of marmin and furanocoumarins derivatives with α-glucosidase, antibacterial and cytotoxic activities
M. Oueslati (2021)
10.1002/AJOC.202100039
Base‐Promoted Direct Cascade Transformation of Chromones to Coumarins via Benzannulation and Transesterification
Hongyun Cai (2021)
10.1039/d1bm00424g
Delivery of novel coumarin-dihydropyrimidinone conjugates through mixed polymeric nanoparticles to potentiate therapeutic efficacy against triple-negative breast cancer.
Avijit Ghosh (2021)
10.1007/s11164-020-04367-6
A synergetic role of Aegle marmelos fruit ash in the synthesis of biscoumarins and 2-amino-4H-chromenes
R. C. Patil (2021)
10.1007/s13738-021-02377-8
Aryl hydrazones linked thiazolyl coumarin hybrids as potential urease inhibitors
Uzma Salar (2021)
10.33448/RSD-V10I3.13430
Synthesis of Ni(II), Cu(II) and Zn(II) coumarin-3-carboxilic acid derivates and their and their physical-chemical properties
Dirceu Aparecido Gonçalves de Souza (2021)
10.5802/CRCHIM.68
Synthesis, structural characterization, biological activity and molecular docking study of 4,7-dihydroxycoumarin modified by aminophenol derivatives
Ziko Milanovic (2021)
10.1016/j.ejmech.2020.113037
Engagement of phytoestrogens in breast cancer suppression: Structural classification and mechanistic approach.
A. Tanwar (2020)
10.1039/d0cp00696c
Interaction of amphiphilic coumarin with DPPC/DPPS lipid bilayer: effects of concentration and alkyl tail length.
Poornima Kalyanram (2020)
10.1007/s13738-020-01999-8
Formation of epoxychromeno[4,3-c]isoquinolines through diastereoselective one-pot IMDA reaction of 4-chloro-3-[(1E)-3-oxo-3-phenyl-1-propen-1-yl]-2H-chromen-2-one and furfurylamine
A. Alizadeh (2020)
10.13005/ojc/370231
Synthesis, characterization, structural exploration and quantum chemical calculations of (E)-8-(1-((4-aminobenzyl)imino)ethyl)-7-hydroxy-4-methyl-coumarin
Chethan Prathap K. N (2020)
10.1039/c9md00570f
Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer.
Shagufta (2020)
10.1016/j.ica.2020.119465
Synthesis, spectroscopic characterization, biological activity, DFT and molecular docking study of novel 4-hydroxycoumarine derivatives and corresponding palladium(II) complexes
Edina H Avdović (2020)
10.1021/acsmaterialslett.0c00455
Functional Dyes in Polymeric 3D Printing: Applications and Perspectives
M. Gastaldi (2020)
10.3390/molecules25235685
Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis
Saad Alghamdi (2020)
10.1177/1934578X20953954
Pharmacological Activities of Coumarin Compounds in Licorice: A Review
Yimei Zang (2020)
10.1186/s43088-020-00059-7
In silico molecular docking studies and MM/GBSA analysis of coumarin-carbonodithioate hybrid derivatives divulge the anticancer potential against breast cancer
Shridhar V Pattar (2020)
10.3390/cancers12071959
Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer
Esra Küpeli Akkol (2020)
10.1186/s43094-020-00062-w
Chemical profiling of a polyherbal formulation by tandem mass spectroscopic analysis with multiple ionization techniques
Sulaiman C. T. (2020)
10.1002/bio.3791
Quantum chemical computations and photophysical spectral features studies of two coumarin compounds.
Kalpana K. Sharma (2020)
10.1002/jhet.4100
Recent progress on coumarinscaffold‐basedanti‐microbial agents (PartIII)
M. Gouda (2020)
10.1016/j.mencom.2020.09.001
Rational synthetic methods in creating promising (hetero)aromatic molecules and materials
G. Zyryanov (2020)
10.1016/j.ejphar.2020.173207
Coumarins modulate the anti-glioma properties of temozolomide.
Joanna Sumorek-Wiadro (2020)
10.3390/cosmetics7040094
Melanogenesis Effect of 7-acetoxy-4-methylcoumarin in B16F10 Melanoma Cells
J. Sim (2020)
10.1016/b978-0-12-819542-0.00010-5
Microwave- and ultrasound-assisted heterocyclics synthesis in aqueous media
H. Abdullah (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar